Capricor Therapeutics investors face a September 28, 2026, deadline to contact the Shareholders Foundation regarding a lawsuit filed on July 30 over alleged securities laws violations. The complaint alleges Capricor adopted changes to the pre-specified statistical analysis plan for analyzing Deramiocel clinical data without the FDA agreeing to those changes before the company resubmitted the treatment’s Biologics License Application. It further alleges the company failed to disclose the resulting risk that the FDA could find the clinical results insufficient to establish substantial evidence of effectiveness, creating a substantial risk to regulatory approval for Duchenne muscular dystrophy. The Shareholders Foundation said the lawsuit seeks to recover losses for certain investors and cautioned that it is not a law firm and that the referenced case is not related to it.